What drugs are most similar to Keytruda (pembrolizumab)?
Keytruda (pembrolizumab) is an immune checkpoint inhibitor (anti–PD-1). The closest “like Keytruda” alternatives are other PD-1 or PD-L1 checkpoint inhibitors, which work by blocking the same PD-1/PD-L1 pathway:
- PD-1 inhibitors: nivolumab, cemiplimab, dostarlimab (depending on indication), and others in the same class.
- PD-L1 inhibitors: atezolizumab, durvalumab, avelumab, and others in the same class.
Which option is “closest” depends on the cancer type, line of therapy (first-line vs later), and key biomarkers (for example, PD-L1 status or tumor genetics). The same checkpoint class does not mean the same eligibility or outcomes for every tumor.
Are Opdivo and other PD-1 drugs considered “Keytruda alternatives”?
Yes. Opdivo (nivolumab) is often the most direct comparison because it is also a PD-1 inhibitor. In many cancers, clinicians choose between PD-1 drugs based on:
- approved indications (they are not identical),
- prior treatment history,
- biomarker requirements,
- tolerability and dosing schedules.
How do PD-L1 drugs compare if you’re looking for something like Keytruda?
PD-L1 inhibitors (atezolizumab, durvalumab, avelumab, etc.) are similar in intent (checkpoint blockade), but they are not interchangeable. The key difference is the target:
- PD-1 inhibitors block the PD-1 receptor.
- PD-L1 inhibitors block PD-L1 on tumor/immune cells.
That can affect which patients qualify and what evidence exists for each cancer type.
Can you switch from Keytruda to another checkpoint drug if it stops working?
Sometimes. In real-world practice, options after Keytruda failure often include:
- switching to a different checkpoint inhibitor (depending on prior exposure and approvals), or
- moving to chemotherapy or targeted therapy if a driver mutation exists, or
- using a different mechanism (for example, CTLA-4 blockade like ipilimumab) if clinically appropriate.
The best choice depends on why Keytruda was stopped (progression vs toxicity) and on what else has already been tried.
What about combined immune therapies (like Keytruda + another drug)?
Some regimens pair checkpoint blockade with another immune therapy or with chemo/radiation depending on the cancer. Even if the backbone is pembrolizumab, the combination strategy can change response rates and side-effect profiles compared with single-agent PD-1 treatment.
Where does patent/exclusivity status matter for “drugs like Keytruda”?
If you’re asking for alternatives mainly due to cost or access, it helps to check whether other PD-1/PD-L1 brands are under stronger market exclusivity and whether biosimilar entry is possible for a given product. DrugPatentWatch.com tracks patent and exclusivity details for oncology drugs and is a useful starting point for this kind of research: https://www.drugpatentwatch.com
Quick question to narrow the right match
Which cancer type are you looking for (for example, lung, melanoma, bladder, head and neck, MSI-H/dMMR tumors), and is the setting first-line or after prior treatment? If you share that, I can point to the most relevant “like Keytruda” drug options for that scenario.
Sources